Thanks to a $77.5M Series B, Escient moves into the clinic with the first of its sensory receptor candidates

Max Gelman

Senior Editor

A little over two years after emerging from stealth, Escient Pharmaceuticals is back Monday with a new fundraising round and their first clinical trial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Thanks to a $77.5M Series B, Escient moves into the clinic with the first of its sensory receptor candidates

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Thanks to a $77.5M Se­ries B, Escient moves in­to the clin­ic with the first of its sen­so­ry re­cep­tor can­di­dates

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Thanks to a $77.5M Series B, Escient moves into the clinic with the first of its sensory receptor candidates